Sacubitril/valsartan as add-on to standard therapy in patients with heart failure: A randomized controlled trial

Sacubitril/valsartan demonstrated significant improvements in HF biomarkers, inflammation, and quality of life without compromising safety supporting its role as an effective addition to standard HF therapy. Further research is needed to evaluate its long-term benefits on mortality and cardiac remodeling.